A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
Inclusion Criteria:
Exclusion Criteria:
Brussels, Brussels Capital 1070, Belgium
Québec, Quebec G1V 4G5, Canada
Otago, Otago 9016, New Zealand
Belgrade, Beograd 11000, Serbia
Nottingham, Nottinghamshire NG5 1PB, United Kingdom
Liverpool, L14 3PE, United Kingdom